DiaSorin, Tecan to Collaborate in New Platform Development
DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent® Laboratory Automation Solution as its nucleic acid extraction platform. The new platform will be used in combination with the DiaSorin Liaison® MDX PCR system to provide the customer with a complete sample to result system for molecular diagnostics.
The Fluent platform, to be supplied through Tecan Partnering, will be optimized for use with DiaSorin extraction chemistry and automated PCR set up of the Liaison MDX 96-well disc. Fluent breaks new ground, delivering more capacity and increased speed. The platform provides exceptional precision, throughput and walkaway time.
Dr David Martyr, CEO of Tecan, commented: “We are delighted that DiaSorin has chosen the Fluent Laboratory Automation Solution as the basis for this new platform. The precision, speed and low volume liquid handling accuracy offered by the Fluent are ideal for molecular diagnostics applications.”
RNA That Helps Grow Blood Vessels Could Aid Heart Disease ResearchNews
STEEL, a noncoding RNA, acts on genes to stimulate produce of blood vessels, a finding which could advance efforts to combat heart disease.READ MORE
Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast CancerNews
A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE